Traders should watch for commercial launch updates and initial prescription uptake by end of 2026. The stock may re-rate as Spero moves from clinical-stage to commercial-stage. Monitor for potential milestone payments from GSK under the license agreement.
SPRO drugs
SPRO drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 23 $2.15entry
- T+1 · 5mo ago −2.33%α −2.28% · $2.10
- T+5 · 5mo ago +5.12%α +4.10% · $2.26
- T+20 · 4mo ago −33.02%α −34.18% · $1.44
- T+60 · 2mo ago −48.37%α −51.62% · $1.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spero Therapeutics and GSK announced FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for complicated UTIs in adults. The approval is based on the PIVOT-PO Phase III trial showing non-inferiority vs IV imipenem-cilastatin. The drug is expected to be available in the US by end of 2026. This is a major product approval for Spero, a clinical-stage biopharma with a $132M market cap, and validates its partnership with GSK.
Key Facts
- FDA approved Utebzi (tebipenem pivoxil) for cUTIs including pyelonephritis on June 17, 2026
- First and only oral carbapenem antibiotic approved in the US
- Approval based on PIVOT-PO Phase III trial demonstrating non-inferiority vs IV imipenem-cilastatin (adjusted treatment difference: -1.3%; 95% CI: -7.5%, 4.8%)
- More than 3 million cases of cUTIs treated annually in the US; a third of patients impacted by resistant infections
- Drug anticipated to be available to US patients by end of 2026
- Approval received one day ahead of PDUFA date of June 18, 2026
- Spero is a clinical-stage biopharma with $132M market cap; no current revenue from approved products
Financial Impact
Transformative for Spero as it transitions from clinical-stage to having an FDA-approved product. The cUTI market represents over $6B in annual US healthcare costs. No specific revenue or deal value disclosed.
Risk Factors
- Commercial launch and market adoption may be slower than anticipated
- Spero is still a small-cap with limited commercial infrastructure; relies on GSK for commercialization
- Competitive landscape for oral antibiotics and potential label limitations
- Forward-looking statements about commercial success are subject to risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-277506 |
| Document: d51395d8k.htm | 0001193125-26-277506 |
| Document: 0001193125-26-277506-index-headers.html | 0001193125-26-277506 |
| Document: 0001193125-26-277506-index.html | 0001193125-26-277506 |
| Document: 0001193125-26-277506.txt | 0001193125-26-277506 |
Track record
17 reports on SPRO
3 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
- Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
- Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
- Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
- Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers